Coldstream Laboratories, Inc. has been awarded a five-year contract with the National Cancer Institute (NCI) for the program, “Development and Production of Parenteral Dosage Forms for Clinical Studies.” The program’s goal is to develop and produce parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.   “The requirements for this program mesh perfectly with Coldstrea...